Breathe Easy: Respiratory Care in Neuromuscular Disorders
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Standards for the Diagnosis and Treatment of Patients with COPD
Copyright #ERSJournals Ltd 2004 EurRespir J 2004;23: 932– 946 EuropeanRespiratory Journal DOI: 10.1183/09031936.04.00014304 ISSN0903-1936 Printedin UK –allrights reserved ATS/ ERSTASK FORCE Standardsfor the diagnosisand treatment of patientswith COPD: asummaryof the ATS/ERSposition paper B.R. Celli*, W. MacNee*,andcommittee members Committeemembers: A Agusti, A Anzueto, B Berg, A S Buist, P M A Calverley, N Chavannes, T Dillard, B Fahy, A Fein, J Heffner, S Lareau, P Meek, F Martinez, W McNicholas, J Muris, E Austegard, R Pauwels, S Rennard, A Rossi, N Siafakas, B Tiep, J Vestbo, E Wouters, R ZuWallack *P ulmonaryand Critical C are D ivision, St Elizabeth s’ Medical Center, Tufts U niversity School of Medicine, Boston, Massachusetts, USA # Respiratory Medicine ELE GI, Colt R esearch Lab Wilkie Building, CONTEMedical Schoo l, T eviot Place, Edinburgh, UK CONTENTSNTS Background. ............................ 932 Managementof stab eCOPD:surgery in and for Goals and objectives 933 COPD.. ............................... 938 Participants 933 Surgery in COPD 938 Evidence, methodology and validation 933 Surgery for COPD 938 Concept of a "live",modular document 933 Managementof stab e COPD: s eep. ........... 938 Organisation of the document 933 Managementof stab eCOPD:air-trave . 939 De® nitionof COPD. ...................... 933 Exacerbationof COPD: de® nition, eva uation and Diagnosisof COPD. ...................... 933 treatment ............................... 939 Epidemio ogy,risk factors andnatura history De® nition 939 ofCOPD ............................... 934 Assessment 940 Patho ogyand pathophysio ogyin COPD . ....... 934 Indication for hospitalisation 940 C inica assessment, testingand differentia diagnosisof Indications for admission to specialised or intensive COPD.. ............................... 934 care unit 940 Medicalhistory 935 Treatment of exacerbations 940 Physicalsigns 935 Exacerbationof COPD: inpatient oxygen therapy. -
United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul
United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul. 9, 1991 54 HYPERBARIC OXYGENATION 4,452,242 6/1984 Bänziger ......................... 128/205.26 APPARATUS AND METHODS 4,467,798 8/1984 Saxon et al. ... ... 128/205.26 4,474,571 10/1984 Lasley ................................... 604/23 75 Inventor: Wallace E. Trammell, Provo, Utah 4,509,513 4/1985 Lasley ....... ... 128/202.12 4,624,656 1 1/1986 Clark et al. ........................... 604/23 73) Assignee: Ballard Medical Products, Midvale, 4,691,.695 9/1987 Birk et al. ............................. 128/38 Utah Appl. No.: 392,169 FOREIGN PATENT DOCUMENTS 21) 317900 12/1919 Fed. Rep. of Germany ... 128/256 22) Filed: Aug. 10, 1989 1 14443 12/1941 United Kingdom ................ 128/248 Related U.S. Application Data OTHER PUBLICATIONS 63 Continuation of Ser. No. 297,351, Jan. 13, 1989, aban TOPOX Literature. doned, which is a continuation of Ser. No. 61,924, Jun. Oxycure Literature. 15, 1987, abandoned, which is a continuation-in-part of B & F Medical Products, Inc. Literature. Ser. No. 865,762, May 22, 1986, abandoned. Primary Examiner-Richard J. Apley (51) Int. Cl. ............................................... A61H 9/00 Assistant Examiner-Linda C. M. Dvorak (52) U.S. Cl. ................................ 128/205.26; 128/30; Attorney, Agent, or Firm-Lynn G. Foster 128/202.12; 128/205.24; 604/23 (58) Field of Search ...................... 128/202. 12, 205.26, 57 ABSTRACT 128/28, 30, 30.2, 38, 40, 402; 600/21; 604/23, A novel hyperbaric oxygenation apparatus, and related 289, 290, 293,304, 305, 308 methods, the apparatus comprising a chamber in the form of a disposable inflatable bag of impervious inex 56 References Cited pensive synthetic resinous material which can be used at U.S. -
Effects of Calcium on Intestinal Mucin: Implications for Cystic Fibrosis
27. Takcbayi~shi.S.. (;robe. II . von B;~ssca~t/.D. H.. and rliormnn. 11. Ultrastruc- prepnratlon.) tural a\pects of veihel .llteratlon\ In homoc!\t~nur~a.V~rcha\r'r Arch. Aht. .A 33 Wong. P. W. K.. Scliworl. V . and Komro~er.(i. M.: The b~os!nthc\~\of P;~thol Anat . 1154- 4 (1071). c)st:~thlonrnc In pntlcntc s~thhornoc!\tinur~,~. Ped~at.Rer . 2- 149 (196x1. 28. T:~ndler. H. T.. I:rlandson. R. A,, and Wbnder. E. 1.. Rihol1;lvln and mou\c 34 'The authors would l~kcto thank K. Curleq, N. Becker, and k.Jaros~u\ for thcir hepatic cell structure and funct~on.hmer. J. Pnthol.. 52 69 (1968). techn~cal:Is\l\tancc and Dr\. B. Chomet. Orville T B:llle!. and Mar) B. 29. Ti~nikawa, L.: llltrastructurnl A\pect\ of the I iver and Its I)~sordcr\(Igaker Buschman for the~ruggehtlona In the ~ntcrpretation\of braln and Iner electron Shoin. I.td.. Tok!o. 1968). micrograph\. 30. Uhlendorl, B. W.. Concrl!. E. R.. and Mudd. S. H.: tlomoc!st~nur~a:Studle, In 35 Th~sstud! &a\ \upported b! Publrc Health Servlcc Kese;~rch Grant no. KO1 tissue culture. Pediat. Kes.. 7: 645 (1073). N5OX532NlN and a grant from the Illino~\Department of Mental llealth. 31. Wong. P. W. K.. and Fresco. R.: T~\suec!\tathlon~nc in mice trei~tedw~th 36 Requests for reprint\ should be i~ddressed to: Paul W. K. Wong. M.D.. cystelne and homoser~ne.Pedlat. Res . 6 172 (1972) Department of Ped~atric.Prcsh!tcr~an-St. -
In Vitro Modelling of the Mucosa of the Oesophagus and Upper Digestive Tract
21 Review Article Page 1 of 21 In vitro modelling of the mucosa of the oesophagus and upper digestive tract Kyle Stanforth1, Peter Chater1, Iain Brownlee2, Matthew Wilcox1, Chris Ward1, Jeffrey Pearson1 1NUBI, Newcastle University, Newcastle upon Tyne, UK; 2Applied Sciences (Department), Northumbria University, Newcastle upon Tyne, UK Contributions: (I) Conception and design: All Authors; (II) Administrative support: All Authors; (III) Provision of study materials or patients: All Authors; (IV) Collection and assembly of data: All Authors; (V) Data analysis and interpretation: All Authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Kyle Stanforth. NUBI, Medical School, Framlington Place, Newcastle University, NE2 4HH, Newcastle upon Tyne, UK. Email: [email protected]. Abstract: This review discusses the utility and limitations of model gut systems in accurately modelling the mucosa of the digestive tract from both an anatomical and functional perspective, with a particular focus on the oesophagus and the upper digestive tract, and what this means for effective in vitro modelling of oesophageal pathology. Disorders of the oesophagus include heartburn, dysphagia, eosinophilic oesophagitis, achalasia, oesophageal spasm and gastroesophageal reflux disease. 3D in vitro models of the oesophagus, such as organotypic 3D culture and spheroid culture, have been shown to be effective tools for investigating oesophageal pathology. However, these models are not integrated with modelling of the upper digestive tract—presenting an opportunity for future development. Reflux of upper gastrointestinal contents is a major contributor to oesophageal pathologies like gastroesophageal reflux disease and Barratt’s oesophagus, and in vitro models are essential for understanding their mechanisms and developing solutions. -
Effect of Assist Negative Pressure Ventilation by Microprocessor
258 ORIGINAL ARTICLE Thorax: first published as 10.1136/thorax.57.3.258 on 1 March 2002. Downloaded from Effect of assist negative pressure ventilation by microprocessor based iron lung on breathing effort M Gorini, G Villella, R Ginanni, A Augustynen, D Tozzi, A Corrado ............................................................................................................................. Thorax 2002;57:258–262 Background: The lack of patient triggering capability during negative pressure ventilation (NPV) may contribute to poor patient synchrony and induction of upper airway collapse. This study was undertaken to evaluate the performance of a microprocessor based iron lung capable of thermistor trig- gering. Methods: The effects of NPV with thermistor triggering were studied in four normal subjects and six patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) by measuring: (1) the time delay (TDtr) between the onset of inspiratory airflow and the start of assisted breathing; (2) the pressure-time product of the diaphragm (PTPdi); and (3) non-triggering inspiratory efforts (NonTrEf). In patients the effects of negative extrathoracic end expiratory pressure (NEEP) added to NPV were also evaluated. See end of article for Results: With increasing trigger sensitivity the mean (SE) TDtr ranged from 0.29 (0.02) s to 0.21 authors’ affiliations ....................... (0.01) s (mean difference 0.08 s, 95% CI 0.05 to 0.12) in normal subjects and from 0.30 (0.02) s to 0.21 (0.01) s (mean difference 0.09 s, 95% CI 0.06 to 0.12) in patients with COPD; NonTrEf ranged Correspondence to: from 8.2 (1.8)% to 1.2 (0.1)% of the total breaths in normal subjects and from 11.8 (2.2)% to 2.5 Dr M Gorini, Via Ragazzi (0.4)% in patients with COPD. -
What Are the Respiratory Requirements for the Treatment of COVID-19 Pneumonia?
What are the respiratory requirements for the treatment of COVID-19 pneumonia? Background What happens in the lungs during COVID-19 pneumonia? Patients may require support of their breathing by having ventilatory assistance for a range of reasons, but patients who are seriously affected by COVID-19 will primarily develop pneumonia which may progress to acute respiratory distress syndrome (ARDS) in which there is extreme inflammation with damage and fluid accumulation within the small gas-exchange sacs of the lung (alveoli).1 These patients require specialised ventilation strategies to prevent hypoxia (oxygen depletion of their tissues) which have been well defined2,3, and which are known to deliver optimum therapy4. How is ventilatory assistance conventionally delivered? Since the first positive pressure devices were introduced in the 1950s, it has become conventional to ventilate the lungs, in a wide variety of disease, by delivering positive pressure ventilatory support, either via a tightly-fitting face mask (CPAP), or through a cuffed endo-tracheal tube using positive pressure ventilators (PPV). These devices have become increasingly sophisticated and a whole generation of anaesthetists/intensivists have become expert in their use. However, before this method was introduced there was a long history of using negative pressure ventilation (NPV) by placing the patient’s body within a chamber with their head outside, with a seal at the neck. The lungs were inflated creating a negative pressure in the chamber or tank (the “iron lung”). NPV mimics and enhances natural respiration. The change from NPV to PPV was not a planned decision related to their relative evidence or efficacy, but occurred because of the convenience of not having to manage a patient inside a large tank, and ironically, a shortage of these large and expensive devices during the polio epidemic during the 1950s. -
Position!Statement:!! Tracheostomy! Management!
! ! The!New!Zealand!Speech/language!Therapists’!Association! (NZSTA)! ! ! ! Position!Statement:!! Tracheostomy! Management! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! Copyright!©!2015!The!New!Zealand!Speech;language!Therapists’!Association!! !!!!! ! Disclaimer:!To!the!best!of!The!New!Zealand!Speech;language!Therapists’!Association’s!(‘the!Association’)! knowledge,!this!information!is!valid!at!the!time!of!publication.!The!Association!makes!no!warranty!or! representation!in!relation!to!the!content!or!accuracy!of!the!material!in!this!publication.!The!Association! expressly!disclaims!any!and!all!liability!(including!liability!for!negligence)!in!respect!of!use!of!the! information!provided.!The!Association!recommends!you!seek!independent!professional!advice!prior!to! making!any!decision!involving!matters!outlined!in!this!publication.!! ! ! ! Acknowledgements! ! Working!party! Lucy!Greig!(lead)! Molly!Kallesen! Melissa!Keesing! Anna!Miles! Turid!Peters! Samantha!Scott! Katie!Ward! !! Speech!Pathology!Australia!for!sharing!Speech&Pathology&Australia.&(2013).& Tracheostomy&Management&Clinical&Guideline.&Melbourne:&Speech&Pathology& Australia.&with!members!of!the!New!Zealand!Speech;language!Therapists’! Association.! !! Advisors! Karen!Brewer,!Speech;language!Therapist,!Te!Kupenga!Hauora!Maori,!Faculty!of! Medical!&!Health!Sciences,!The!University!of!Auckland.! ! Erena!Wikaire,!Physiotherapist,!Te!Kupenga!Hauora!Maori,!Faculty!of!Medical!&! Health!Sciences,!The!University!of!Auckland.! ! Reviewers! The!New!Zealand!Speech;language!Therapists’!Association!Executive!Committee! -
Respiratory Failure Diagnosis Coding
RESPIRATORY FAILURE DIAGNOSIS CODING Action Plans are designed to cover topic areas that impact coding, have been the frequent source of errors by coders and usually affect DRG assignments. They are meant to expand your learning, clinical and coding knowledge base. INTRODUCTION Please refer to the reading assignments below. You may wish to print this document. You can use your encoder to read the Coding Clinics and/or bookmark those you find helpful. Be sure to read all of the information provided in the links. You are required to take a quiz after reading the assigned documents, clinical information and the Coding Clinic information below. The quiz will test you on clinical information, coding scenarios and sequencing rules. Watch this video on basics of “What is respiration?” https://www.youtube.com/watch?v=hc1YtXc_84A (3:28) WHAT IS RESPIRATORY FAILURE? Acute respiratory failure (ARF) is a respiratory dysfunction resulting in abnormalities of tissue oxygenation or carbon dioxide elimination that is severe enough to threaten and impair vital organ functions. There are many causes of acute respiratory failure to include acute exacerbation of COPD, CHF, asthma, pneumonia, pneumothorax, pulmonary embolus, trauma to the chest, drug or alcohol overdose, myocardial infarction and neuromuscular disorders. The photo on the next page can be accessed at the link. This link also has complete information on respiratory failure. Please read the information contained on this website link by NIH. 1 http://www.nhlbi.nih.gov/health/health-topics/topics/rf/causes.html -
The Following Information Was Take From
The following excerpt has been taken from the Christopher & Dana Reeve Foundation Paralysis Resource Center website. http://www.christopherreeve.org/site/c.mtKZKgMWKwG/b.4453421/k.9F9F/Respiratory .htm Respiratory, Ventilator and Trach Resources As we breathe, oxygen in the air is brought into the lungs and into close contact with the blood, which absorbs it and carries it to all parts of the body. At the same time, the blood gives up carbon dioxide, which is carried out of the lungs with air breathed out. Lungs are not affected by paralysis. However, the muscles of the chest, abdomen, and diaphragm can be affected. As the various breathing muscles contract, they allow the lungs to expand, which changes the pressure inside the chest so that air rushes into the lungs. This is inhaling – which requires muscle strength. As those same muscles relax, the air flows back out of your lungs, and you exhale. If paralysis occurs at the C-3 level or higher, the phrenic nerve is no longer stimulated and therefore the diaphragm does not function. This means mechanical assistance -- usually a ventilator – will be needed to breathe. Persons with paralysis at the mid-thoracic level and higher will have trouble taking a deep breath and exhaling forcefully. Because they don’t have use of abdominal or intercostal muscles, these people have also lost the ability to forcefully cough. This can lead to lung congestion and respiratory infections. Moreover, secretions can act as glue, causing the sides of your airways to stick together and not inflate properly. This is called atelectasis, or a collapse of part of the lung. -